Developer docs
API playgroundTry for free, no card

Search company profiles

cdkl5 research collaborative

Full company profile

uuid02memu2

Namestring
cdkl5 research collaborative
Legal namestring
CDKL5 Research Collaborative
Company typeenum
Private
Founded yearint
2017
Descriptiontext

CDKL5 Research Collaborative is a 501(c)(3) non-profit organization founded in 2017 and headquartered in Dexter, Michigan, dedicated to advancing clinical research and patient advocacy for CDKL5 Deficiency Disorder, an ultra-rare genetic epilepsy. The organization operates as an all-volunteer entity with no paid staff, channeling donor contributions into research grants, clinical infrastructure, and family-support resources for an internationally distributed population of affected families.

The Collaborative runs six core programs: the Kiera's Hope Project (a sub-brand supporting affected families), a Clinical Research Funding Program that distributes grants to investigators, the CDKL5 Database and Registry developed in partnership with the UPenn Orphan Disease Center, a Clinical Trial Information Service, the CDKL5 Centers of Excellence Network spanning multiple pediatric hospitals, and a Therapies Resource Hub. A Scientific Advisory Board drawn from UCSD, Harvard, UT Southwestern, UPenn, and Anavex provides research governance and credibility.

Its business model is donation-funded rather than revenue-generating. Funding is sourced from individual donors, fundraising events, and selective pharmaceutical sponsorships — including Marinus Pharmaceuticals for the Marigold Study. The organization has earned the Candid Platinum Seal of Transparency annually from 2018 through 2025, signaling sustained governance and disclosure quality. As a non-profit patient advocacy organization, it has no commercial product, no pricing model, and no AI or technology stack; its competitive position rests on community coordination, scientific advisory talent, and institutional partnerships.

Short descriptiontext

CDKL5 Research Collaborative is a 501(c)(3) non-profit founded in 2017 that funds clinical research, operates a disease registry and Centers of Excellence network, and supports families affected by CDKL5 Deficiency Disorder, a rare genetic epilepsy.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersDexter, United States
HQ citystring
Dexter
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease advocacy, clinical research funding, patient registry services, nonprofit health organization, family support services
Industry1 code
PRIMARYHLACAIAH
Clinical Data Repositories (CDR) & Longitudinal Patient Records
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare Data Platforms, Warehousing & Governance
NAICS code3 codes
  • Other Individual and Family Services62419
  • Individual and Family Services6241
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Misc Health & Allied Services, Nec8090
  • Services-Social Services8300
Product category
Rare Disease Patient Advocacy & Family Support
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Donations
TypeOthers
Description

Tax-deductible donations from individuals, families, and supporters. Organization is a 501(c)(3) non-profit with EIN# 82-2453342. Maximum donation impact due to all-volunteer staff and minimal overhead.

cdkl5research.org
2Fundraising Events
TypeOthers
Description

Community fundraising events organized by volunteers to generate donations and awareness for the CDKL5 community.

cdkl5research.org
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 record
1Kiera's Hope Project
Description

A project dedicated to spreading hope and possibility, honoring the founder's daughter Kiera who inspired everything the organization does. Focuses on clinical research in communication, epilepsy, neuroplasticity, and arts enrichment for CDKL5 patients.

cdkl5research.org
Core offering1 text field

CDKL5 Research Collaborative is an all-volunteer 501(c)(3) non-profit that funds innovative clinical research on CDKL5 Deficiency Disorder, maintains a patient registry and database with the University of Pennsylvania Orphan Disease Center, curates information on clinical trials, curates a directory of CDKL5 Centers of Excellence at leading pediatric hospitals, and provides families with educational resources, therapy information, and a sub-brand called Kiera's Hope Project focused on arts enrichment and quality-of-life interventions.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

CDKL5 Research Collaborative is a non-profit organization (501(c)(3)) founded in 2017, operating as a single focused initiative rather than a platform-plus-modules architecture. The organization provides a comprehensive web platform for CDKL5 Deficiency Disorder research funding, family support, and education. Key offerings include the Kiera's Hope Project sub-brand focused on inspirational support and arts enrichment, a Clinical Research Funding Program offering grants for epilepsy and neuroplasticity research, a CDKL5 Database and Registry in partnership with UPenn, clinical trial information services (including the Marigold Study), a network of CDKL5 Centers of Excellence, and a Therapies Resource Hub. The organization is led by families directly impacted by CDKL5 disorder and focuses on clinical care and advocacy for this rare X-linked genetic condition affecting approximately several thousand cases worldwide.

Product and service7 records
1Kiera's Hope Project
CategoryFamily support and arts enrichment sub-brand
Description

Sub-initiative of CDKL5 Research Collaborative dedicated to spreading hope, honoring founder Katheryn's daughter Kiera, pursuing research in communication, epilepsy, and neuroplasticity, and enriching the lives of children with CDKL5 through arts and humanities programs.

2Clinical Research Funding Program
CategoryResearch grant program
Description

Grant and funding program supporting innovative clinical research for CDKL5 Deficiency Disorder, including center-based, community, and educational settings, with emphasis on epilepsy, neuroplasticity, and neuro-abilitation. Awards grants through annual Requests for Proposals (e.g., 2026 RFP posted in 2025).

3CDKL5 Deficiency Disorder Database and Registry
CategoryPatient registry
Description

Patient registry and database collecting data, clinical information, and demographics of those affected by CDKL5 Disorder, operated in partnership with the University of Pennsylvania Orphan Disease Center to understand natural history and direct research efforts.

4Clinical Trial Information Service
CategoryClinical trial information resource
Description

Resource providing information about ongoing CDKL5 clinical trials, including the Marigold Study (pivotal global clinical trial of Ganaxolone by Marinus Pharmaceuticals for treatment of epilepsy in CDKL5 Deficiency Disorder).

5CDKL5 Centers of Excellence Network
CategoryClinic directory
Description

Directory of designated multidisciplinary CDKL5 Centers of Excellence at leading US pediatric hospitals, including Children's Hospital Colorado, Boston Children's Hospital, Cleveland Clinic, St. Louis Children's Hospital, UCLA, NYU Langone, CHOP, and Texas Children's Hospital.

6Therapies Resource Hub
CategoryTherapy education resource
Description

Resource center providing information about various therapies for CDKL5 patients, including Physical Therapy, Speech Therapy, Occupational Therapy, Vision Therapy, Music Therapy, Sensory Therapy, Hippotherapy, Aqua Therapy, and Massage Therapy.

7CDKL5 Research Collaborative Website
CategoryInformational website
Description

Primary public web platform providing information about CDKL5 Deficiency Disorder, research funding opportunities, family resources, clinical trial information, CDKL5 Centers of Excellence listings, and donation collection for the non-profit.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
1CDKL5 Alliance
Strategic tierCoreTypeStrategic or Co-development Partner
Description

CDKL5 Research Collaborative is a member of the global CDKL5 Alliance, collaborating with international CDKL5 organizations to advance research and support for families worldwide.

cdkl5research.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Member of Global Genes, a leading rare disease patient advocacy organization, providing connection to broader rare disease community resources and advocacy efforts.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership for CDKL5 Deficiency Disorder Database and Registry - collection of data, clinical information and demographics of those affected by CDKL5 Disorder to understand natural history and direct research efforts.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership for the Marigold Study - pivotal global clinical trial of Ganaxalone, a novel neurosteroid, for treatment of epilepsy in CDKL5 Deficiency Disorder.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

First CDKL5 Center of Excellence established in 2014 within the Rett Clinic, under direction of Tim Benke MD. Multidisciplinary clinic for evaluation and treatment of CDKL5 patients.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

CDKL5 Center of Excellence under leadership of Heather Olson MD. Multidisciplinary clinic seeing patients from across the US and internationally, actively participating in CDKL5 research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

CDKL5 Center of Excellence headed by Elia Pestana Knight MD. 'Clinic without walls' offering multidisciplinary evaluation and treatment for CDKL5.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Home to Rett Spectrum Clinic where Judith Weisenberg MD and Robin Ryther MD/PHD evaluate and treat children with CDKL5 deficiency, with large augmentative communication team.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Foundation raises funds and awards grants to help children with special needs access life-changing intensive pediatric physical therapy treatment at Euro-Peds.

10CDKL5 Organizations Worldwide
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Connected to global network of CDKL5 organizations including CDKL5 Alliance Francophone, CDKL5 UK, CDKL5 Canada, CDKL5 Japan, CDKL5 Germany, International Foundation for CDKL5 Research, and others.

cdkl5research.org
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Leading rare-disease patient advocacy organization of which CRC is a member. Provides cross-disorder convening, advocacy tooling, and rare-disease awareness programming analogous to CRC's community-led model.

TypeEmerging player
Description

Highly active patient-driven research foundation focused on Rett syndrome, a closely related neurodevelopmental disorder with overlapping gene pathway (MECP2/CDKL5 axis). Comparable model — affected-families-led, venture philanthropy-style research funding, deep pharma relationships — and overlapping clinical and scientific talent.

TypeDirect peer
Description

Private foundation dedicated to CDKL5 Deficiency Disorder, funding gene therapy and translational research at significant scale. Direct competitor for donor mindshare, scientific talent, and pharma partnerships in CDKL5.

4CDKL5 UK
TypeRegional player
Description

UK-based CDKL5 patient advocacy organization affiliated with the CDKL5 Alliance. Operates the same mission and family-support model in the UK/European geography, with overlapping scientific advisory and pharma relationships.

TypeBroad incumbent
Description

Umbrella rare-disease advocacy organization in the US; CRC engages the broader rare-disease policy and funding ecosystem through this network. Comparable mission framing around patient advocacy and orphan-drug development.

TypeOthers
Description

Academic partner hosting the CDKL5 Database and Registry. Functions as enabling infrastructure for CRC's registry and natural-history research program rather than a direct competitor.

TypeBroad incumbent
Description

Larger, more established Rett syndrome advocacy and research organization. Operates a broader portfolio of programs across research, family support, and clinics, analogous to where CRC could scale within CDKL5.

TypeBroad incumbent
Description

Policy-focused rare-disease advocacy organization advancing newborn screening, orphan-drug legislation, and FDA engagement. Comparable advocacy function in the same orphan-drug ecosystem CRC operates in.

9International Foundation for CDKL5 Research (IFCR)
TypeDirect peer
Description

Predecessor organization co-founded by CRC's founder; the other leading CDKL5-focused research and advocacy foundation in the US. Directly comparable mission, donor base overlap, and scientific advisory talent pool.

10CDKL5 Alliance
TypeDirect peer
Description

Umbrella alliance of CDKL5 patient organizations worldwide of which CRC is a member. Coordinates cross-country advocacy and shares the same patient/family constituency.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

cdkl5 research collaborative

Rare Disease Patient Advocacy & Family Supportcdkl5research.org

CDKL5 Research Collaborative is a 501(c)(3) non-profit founded in 2017 that funds clinical research, operates a disease registry and Centers of Excellence network, and supports families affected by CDKL5 Deficiency Disorder, a rare genetic epilepsy.

What cdkl5 research collaborative does

CDKL5 Research Collaborative is a 501(c)(3) non-profit organization founded in 2017 and headquartered in Dexter, Michigan, dedicated to advancing clinical research and patient advocacy for CDKL5 Deficiency Disorder, an ultra-rare genetic epilepsy. The organization operates as an all-volunteer entity with no paid staff, channeling donor contributions into research grants, clinical infrastructure, and family-support resources for an internationally distributed population of affected families.

The Collaborative runs six core programs: the Kiera's Hope Project (a sub-brand supporting affected families), a Clinical Research Funding Program that distributes grants to investigators, the CDKL5 Database and Registry developed in partnership with the UPenn Orphan Disease Center, a Clinical Trial Information Service, the CDKL5 Centers of Excellence Network spanning multiple pediatric hospitals, and a Therapies Resource Hub. A Scientific Advisory Board drawn from UCSD, Harvard, UT Southwestern, UPenn, and Anavex provides research governance and credibility.

Its business model is donation-funded rather than revenue-generating. Funding is sourced from individual donors, fundraising events, and selective pharmaceutical sponsorships — including Marinus Pharmaceuticals for the Marigold Study. The organization has earned the Candid Platinum Seal of Transparency annually from 2018 through 2025, signaling sustained governance and disclosure quality. As a non-profit patient advocacy organization, it has no commercial product, no pricing model, and no AI or technology stack; its competitive position rests on community coordination, scientific advisory talent, and institutional partnerships.

cdkl5 research collaborative firmographics

Firmographics
Name
cdkl5 research collaborative
Legal name
CDKL5 Research Collaborative
Website
https://cdkl5research.org
Company type
Private
Founded year
2017
Operating status
Operating
Short description
CDKL5 Research Collaborative is a 501(c)(3) non-profit founded in 2017 that funds clinical research, operates a disease registry and Centers of Excellence network, and supports families affected by CDKL5 Deficiency Disorder, a rare genetic epilepsy.
Ownership category
akta.pro rank

cdkl5 research collaborative industry classification

Industry
Product category
Rare Disease Patient Advocacy & Family Support
NAICS
Other Individual and Family Services (62419), Individual and Family Services (6241), Scientific Research and Development Services (5417)
SIC
Services-Misc Health & Allied Services, Nec (8090), Services-Social Services (8300)
akta.pro industry
PRIMARYHLACAIAH
Clinical Data Repositories (CDR) & Longitudinal Patient Records
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare Data Platforms, Warehousing & Governance

Keywords

  • Rare disease advocacy
  • Clinical research funding
  • Patient registry services
  • Nonprofit health organization
  • Family support services

Where cdkl5 research collaborative is headquartered

Location

Headquarters

HQ city
Dexter
HQ country
United States
HQ region
North America

Offices1 record

Markets served

cdkl5 research collaborative business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Donations: Tax-deductible donations from individuals, families, and supporters. Organization is a 501(c)(3) non-profit with EIN# 82-2453342. Maximum donation impact due to all-volunteer staff and minimal overhead.
  2. Fundraising Events: Community fundraising events organized by volunteers to generate donations and awareness for the CDKL5 community.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

cdkl5 research collaborative product offering

Product offering

Core offering

CDKL5 Research Collaborative is an all-volunteer 501(c)(3) non-profit that funds innovative clinical research on CDKL5 Deficiency Disorder, maintains a patient registry and database with the University of Pennsylvania Orphan Disease Center, curates information on clinical trials, curates a directory of CDKL5 Centers of Excellence at leading pediatric hospitals, and provides families with educational resources, therapy information, and a sub-brand called Kiera's Hope Project focused on arts enrichment and quality-of-life interventions.

Product overview

CDKL5 Research Collaborative is a non-profit organization (501(c)(3)) founded in 2017, operating as a single focused initiative rather than a platform-plus-modules architecture. The organization provides a comprehensive web platform for CDKL5 Deficiency Disorder research funding, family support, and education. Key offerings include the Kiera's Hope Project sub-brand focused on inspirational support and arts enrichment, a Clinical Research Funding Program offering grants for epilepsy and neuroplasticity research, a CDKL5 Database and Registry in partnership with UPenn, clinical trial information services (including the Marigold Study), a network of CDKL5 Centers of Excellence, and a Therapies Resource Hub. The organization is led by families directly impacted by CDKL5 disorder and focuses on clinical care and advocacy for this rare X-linked genetic condition affecting approximately several thousand cases worldwide.

Differentiator

Problem solved

Functional benefit

Brands

  • Kiera's Hope Project: A project dedicated to spreading hope and possibility, honoring the founder's daughter Kiera who inspired everything the organization does. Focuses on clinical research in communication, epilepsy, neuroplasticity, and arts enrichment for CDKL5 patients.

Products and services

  • Kiera's Hope Project Sub-initiative of CDKL5 Research Collaborative dedicated to spreading hope, honoring founder Katheryn's daughter Kiera, pursuing research in communication, epilepsy, and neuroplasticity, and enriching the lives of children with CDKL5 through arts and humanities programs.
  • Clinical Research Funding Program Grant and funding program supporting innovative clinical research for CDKL5 Deficiency Disorder, including center-based, community, and educational settings, with emphasis on epilepsy, neuroplasticity, and neuro-abilitation. Awards grants through annual Requests for Proposals (e.g., 2026 RFP posted in 2025).
  • CDKL5 Deficiency Disorder Database and Registry Patient registry and database collecting data, clinical information, and demographics of those affected by CDKL5 Disorder, operated in partnership with the University of Pennsylvania Orphan Disease Center to understand natural history and direct research efforts.
  • Clinical Trial Information Service Resource providing information about ongoing CDKL5 clinical trials, including the Marigold Study (pivotal global clinical trial of Ganaxolone by Marinus Pharmaceuticals for treatment of epilepsy in CDKL5 Deficiency Disorder).
  • CDKL5 Centers of Excellence Network Directory of designated multidisciplinary CDKL5 Centers of Excellence at leading US pediatric hospitals, including Children's Hospital Colorado, Boston Children's Hospital, Cleveland Clinic, St. Louis Children's Hospital, UCLA, NYU Langone, CHOP, and Texas Children's Hospital.
  • Therapies Resource Hub Resource center providing information about various therapies for CDKL5 patients, including Physical Therapy, Speech Therapy, Occupational Therapy, Vision Therapy, Music Therapy, Sensory Therapy, Hippotherapy, Aqua Therapy, and Massage Therapy.
  • CDKL5 Research Collaborative Website Primary public web platform providing information about CDKL5 Deficiency Disorder, research funding opportunities, family resources, clinical trial information, CDKL5 Centers of Excellence listings, and donation collection for the non-profit.

Companies that use cdkl5 research collaborative

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

cdkl5 research collaborative technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

cdkl5 research collaborative partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and minor.

  • CDKL5 AlliancecoreStrategic or Co-development PartnerCDKL5 Research Collaborative is a member of the global CDKL5 Alliance, collaborating with international CDKL5 organizations to advance research and support for families worldwide.
  • Global GenescoreStrategic or Co-development PartnerMember of Global Genes, a leading rare disease patient advocacy organization, providing connection to broader rare disease community resources and advocacy efforts.
  • University of Pennsylvania Orphan Disease CentercoreStrategic or Co-development PartnerPartnership for CDKL5 Deficiency Disorder Database and Registry - collection of data, clinical information and demographics of those affected by CDKL5 Disorder to understand natural history and direct research efforts.
  • Marinus PharmaceuticalscoreStrategic or Co-development PartnerPartnership for the Marigold Study - pivotal global clinical trial of Ganaxalone, a novel neurosteroid, for treatment of epilepsy in CDKL5 Deficiency Disorder.
  • Children's Hospital ColoradocoreStrategic or Co-development PartnerFirst CDKL5 Center of Excellence established in 2014 within the Rett Clinic, under direction of Tim Benke MD. Multidisciplinary clinic for evaluation and treatment of CDKL5 patients.
  • Boston Children's HospitalcoreStrategic or Co-development PartnerCDKL5 Center of Excellence under leadership of Heather Olson MD. Multidisciplinary clinic seeing patients from across the US and internationally, actively participating in CDKL5 research.
  • Cleveland CliniccoreStrategic or Co-development PartnerCDKL5 Center of Excellence headed by Elia Pestana Knight MD. 'Clinic without walls' offering multidisciplinary evaluation and treatment for CDKL5.
  • St. Louis Children's Hospital / Washington UniversitycoreStrategic or Co-development PartnerHome to Rett Spectrum Clinic where Judith Weisenberg MD and Robin Ryther MD/PHD evaluate and treat children with CDKL5 deficiency, with large augmentative communication team.
  • Euro-Peds FoundationminorStrategic or Co-development PartnerFoundation raises funds and awards grants to help children with special needs access life-changing intensive pediatric physical therapy treatment at Euro-Peds.
  • CDKL5 Organizations WorldwidecoreStrategic or Co-development PartnerConnected to global network of CDKL5 organizations including CDKL5 Alliance Francophone, CDKL5 UK, CDKL5 Canada, CDKL5 Japan, CDKL5 Germany, International Foundation for CDKL5 Research, and others.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

cdkl5 research collaborative competitors and assessment

Company assessment

Broad incumbents

  • Global Genes: Leading rare-disease patient advocacy organization of which CRC is a member. Provides cross-disorder convening, advocacy tooling, and rare-disease awareness programming analogous to CRC's community-led model.
  • National Organization for Rare Disorders (NORD): Umbrella rare-disease advocacy organization in the US; CRC engages the broader rare-disease policy and funding ecosystem through this network. Comparable mission framing around patient advocacy and orphan-drug development.
  • International Rett Syndrome Foundation: Larger, more established Rett syndrome advocacy and research organization. Operates a broader portfolio of programs across research, family support, and clinics, analogous to where CRC could scale within CDKL5.
  • EveryLife Foundation for Rare Diseases: Policy-focused rare-disease advocacy organization advancing newborn screening, orphan-drug legislation, and FDA engagement. Comparable advocacy function in the same orphan-drug ecosystem CRC operates in.

Emerging players

  • Rett Syndrome Research Trust: Highly active patient-driven research foundation focused on Rett syndrome, a closely related neurodevelopmental disorder with overlapping gene pathway (MECP2/CDKL5 axis). Comparable model — affected-families-led, venture philanthropy-style research funding, deep pharma relationships — and overlapping clinical and scientific talent.

Direct peers

  • Loulou Foundation: Private foundation dedicated to CDKL5 Deficiency Disorder, funding gene therapy and translational research at significant scale. Direct competitor for donor mindshare, scientific talent, and pharma partnerships in CDKL5.
  • International Foundation for CDKL5 Research (IFCR): Predecessor organization co-founded by CRC's founder; the other leading CDKL5-focused research and advocacy foundation in the US. Directly comparable mission, donor base overlap, and scientific advisory talent pool.
  • CDKL5 Alliance: Umbrella alliance of CDKL5 patient organizations worldwide of which CRC is a member. Coordinates cross-country advocacy and shares the same patient/family constituency.

Regional players

  • CDKL5 UK: UK-based CDKL5 patient advocacy organization affiliated with the CDKL5 Alliance. Operates the same mission and family-support model in the UK/European geography, with overlapping scientific advisory and pharma relationships.

Others

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

cdkl5 research collaborative social profiles

Digital presence

cdkl5 research collaborative compliance and trust

Trust signal

Compliance2 records

cdkl5 research collaborative financial estimates

Financial estimate

Revenue estimate

Valuation estimate

cdkl5 research collaborative leadership team

Management profile

Number of profiles

Profiles12 records

cdkl5 research collaborative funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

cdkl5 research collaborative M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about cdkl5 research collaborative

What does cdkl5 research collaborative do?

CDKL5 Research Collaborative is an all-volunteer 501(c)(3) non-profit that funds innovative clinical research on CDKL5 Deficiency Disorder, maintains a patient registry and database with the University of Pennsylvania Orphan Disease Center, curates information on clinical trials, curates a directory of CDKL5 Centers of Excellence at leading pediatric hospitals, and provides families with educational resources, therapy information, and a sub-brand called Kiera's Hope Project focused on arts enrichment and quality-of-life interventions.

Is cdkl5 research collaborative a public or private company?

cdkl5 research collaborative is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was cdkl5 research collaborative founded?

cdkl5 research collaborative was founded in 2017.

Where is cdkl5 research collaborative based?

cdkl5 research collaborative is headquartered in Dexter, United States, in the North America region.

How does cdkl5 research collaborative make money?

Two revenue lines are on record. Donations are the primary driver. The others are fundraising Events.

Who are cdkl5 research collaborative's main competitors?

Broad incumbents on record are Global Genes, National Organization for Rare Disorders (NORD), International Rett Syndrome Foundation and EveryLife Foundation for Rare Diseases. Rett Syndrome Research Trust is listed as an emerging player. Direct peers are Loulou Foundation, International Foundation for CDKL5 Research (IFCR) and CDKL5 Alliance. CDKL5 UK is listed as a regional player. Orphan Disease Center (University of Pennsylvania) is listed as an others.

Does cdkl5 research collaborative have an API?

No public API is recorded for cdkl5 research collaborative.

What industry is cdkl5 research collaborative in?

cdkl5 research collaborative's product category is Rare Disease Patient Advocacy & Family Support. Its primary akta.pro industry code is HLACAIAH, Clinical Data Repositories (CDR) & Longitudinal Patient Records. Its NAICS code is 62419 and its SIC code is 8090.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales